🌟This is history ⭐️The most awaited abstract 👏 Standing ovation at Hall B1 💊 Daraxonrasib becomes the new standard of care for patients with previously treated metastatic #pancreatic #cancer #ASCO26

ALK-positive NSCLC remains one of the most rapidly evolving spaces in thoracic oncology. 🫁 Interesting data from the multicenter retrospective study led by @SWaliany evaluating continuation of next-generation ALK TKIs alongside platinum/pemetrexed chemotherapy after progression. The study suggested potential improvements in PFS/OS and reduced CNS progression, particularly in patients treated upfront with 2G/3G ALK inhibitors. Team ALKItects @PatelOncology #Fellowsforum @benlevylungdoc @Jani_Chinmay

Closing US Focus Meeting on Lung Cancer in Nashville with panels on fusions and rare tumors with experts like Drs. @christine_lovly @JessicaJLinMD @SWaliany @ShirishGadgeel @chulkimMD @LudaBazhenovaMD @MMarmarelis - thanks to all who helped make the meeting such a success!

With multiple MTA-cooperative #PRMT5i now in phase 1/2 trials, MTAP testing should be considered in oncogene-driven #NSCLC. More than 1 in 3 patients with ALK disease may harbor MTAP loss. Next step: TKI PRMT5i combination trials. @DanaFarber @GustaveRoussy @AlkRos1France @ALKPositiveinc

Please (re)watch the powerful Special Speech delivered by Dr. Ross Camidge @DRCamidge at #TTLC26 @IASLC An internationally renowned thoracic oncologist, Dr. Camidge shared something profoundly personal: his own diagnosis and treatment journey with stage IV #EGFR-mutant #NSCLC. His reflections were thoughtful and deeply human. It is a reminder that before we are physicians or patients, we are human beings: vulnerable yet resilient. Please: ❤️ Act with urgency. ❤️ Treat with respect and gentleness. ❤️ Move forward with courage and hope. @ShirishGadgeel @lungoncdoc @KarenReckampMD @TejasPatilMD

A new first line standard of care for HER2 mutant NSCLC? Zongertinib receives accelerated approval as initial therapy based on Beamion LUNG-1 trial with 1L RR 76%. Part of the new FDA voucher program, approval granted 44 days after filing! fda.gov/news-events/press-an…

Update for RET NSCLC @CCR_AACR describes acquired resistance to selective RET inhibitors. The "RETgistry" included 109 pts with post-SRI biopsies and showed 14% with secondary RET mutations. Off target included MET (18%), KRAS (7%), CDKN2A/B (5%). aacrjournals.org/clincancerr…

Great insights from @JuliaRotow at #MaTOS on managing #ALK #NSCLC w/ lorlatinib beyond PD LAT vs systemic therapy. Timely, with new data from @SWaliany and our group showing the safety and activity of adding chemotherapy to next-gen ALK TKIs.@OncoAlert doi.org/10.6004/jnccn.2025.7…

Continuing ALK TKIs when starting chemotherapy for disease progression improves outcomes for patients with advanced ALK NSCLC. Thank you @SWaliany and @JessicaJLinMD for spearheading the effort and including us in this important work! jnccn.org/view/journals/jncc…

Fun reunion with two of my all-time best recruits to @StanfordMedRes & emerging super⭐️ physician-scientists @HanZhuMD & @SWaliany. The original team who launched the ICI-myocarditis troponin screening program @StanfordMed & @StanfordCancer! #AHA25 #CardioOnc

It was an honor to present, on behalf of the co-investigators, the planned OS results from FLAURA2 ph III at #WCLC25. These results confirm a shift in our first-line practice for our EGFRm pts, marking the first time a study has achieved a significant benefit mOS of 4Y. #EGFR

Dr. Jonathan Goldman presents the HARMONi data at #WCLC25. In EGFR NSCLC post TKI, adding ivonescimab (VEGF/PD1 bispecific) improves PFS (4.4 to 6.8m, HR 0.52). Numeric difference in OS in Western pts, but complicated analysis in heterogenous group. Improvement over MARIPOSA2?

#WCLC25 Presidential Superb FLAURA2 OS discussion by @danieltanmd, main questions: - combo may ⬆️likelihood of long-term response? - clinical/molec/ctDNA factors relevant - refinement needs complex integration of factors Extremely elegant slides, I plan to use 😃 @IASLC #LCSM

E4512: adjuvant crizotinib for resected stage II-III ALK NSCLC #DavidGerber. Insightful discussion by @JessicaJLinMD #WCLC25 💠Adjuvant crizotinib did not prolong median DFS 💠Biomarkers still critical for early-stage NSCLC given role of TKIs eg. osi (ADAURA) & alectinib (ALINA)

Awaited results of HARMONi trial evaluating ivonescimab, a PD1/VEGF bispecific presented by Dr. Jonathan Goldman presented @IASLC #WCLC25 🔹PFS HR 0.52 🔹OS immature How will this fit into a packed landscape of chemo, ADCs and amivantamab based therapy? It remains important to still test for mutations upon PD

Exciting #ARROS1 phase 1/2 trial results of #zidesamtinib in ROS mNSCLC #WCLC25 @alexdrilon 💠Active in heavily pretreated pts: ORR 44% after 1-4 prior ROS1 TKIs; 51% after 1 prior TKI (criz or entrect) 💠Responses after prior repotrectinib & taletrectinib; active against G2032R

Exciting final overall survival analysis of FLAURA2: osi PT/pem vs osi alone for #EGFRm NSCLC #WCLC25 @dplanchard 💠⬆️OS with osi/CTx (median 47.5 mo) vs osi (37.6 mo) 💠Benefit despite median exposure to pem 8.3 mo & most pts in control arm receiving subsequent PT-based chemo

At NOSCM, @JuliaRotow presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled

🌓Yin&Yang Masterclass 2025 1st edition comes to an end. Huge thanks to all young and early-career investigators for stepping up, and to the stellar faculty for guiding them with passion and vision. Next stop: Paris 2026 🇨🇵 Stay tuned! #YinYang2025 @mihaela_aldea @BRicciutiMD

Enjoyed participating in the session on adjuvant #EGFR & #ALK TKI at Yin & Yang Lung Cancer Masterclass w/ @Tony_Calles & @MarianaBrandao0 w/ important debate on role of adjuvant chemo prior to TKI. Thanks to @mihaela_aldea @RobertoFerrara_ @BRicciutiMD for the chance to present!